Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Intas Pharmaceuticals Ltd. has said it will give up to 2,000,000 tablets of hydroxychloroquine to World Health Organization-supported examination into the avoidance of COVID-19 contamination utilizing hydroxychloroquine, for nothing out of pocket, alongside 2,000,000 tablets of coordinated fake treatment.
Intas educated that it is teaming up on the WHO-embraced study utilizing hydroxychloroquine, a medication that may have an impact in forestalling as well as lessening indications of COVID-19. The worldwide COPCOV (chloroquine/hydroxychloroquine avoidance of COVID-19 in the social insurance setting; a randomized, fake treatment controlled prophylaxis) study includes 40,000 bleeding edge human services laborers who are thinking about COVID-19 patients and is because of start right away.
Binish Chudgar, VC at Intas Pharmaceuticals Ltd. said notwithstanding giving logical counsel, the organization’s groups are staying at work longer than required to produce the necessary hydroxychloroquine and coordinating fake treatment for this indispensable examination.
